Tis, perhaps another teak of ANLY from Marc…..perhaps the Thinkolator can sniff it out.
Today I’m going ”all in” on a medical company from Massachusetts.
I love this play. It’s a company I’ve been monitoring for a full decade, waiting until the time was exactly right before recommending it.
Today, this company has $1.28 BILLION in cash and no debt.
A rare FDA classification (only four of which have been handed out per year on average since 1906) recently gave it a seven-year monopoly.
Better yet, it has seven different drugs that could be worth an average $329.8 million each based on my estimates.
This company is behind one of the most shocking medical developments ever.
One Nobel Prize laureate called the initial discovery of the technology this company utilizes ”the most important and exciting breakthrough of the last decade, perhaps multiple decades.”
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.